Геморрагические лихорадки: противовирусные эффекты и молекулярные мишени биологически активных полисахаридов и лектинов из морских гидробионтов

Поиск и создание этиотропных препаратов является одной из важнейших задач современной вирусолологии. В настоящем обзоре рассматриваются противовирусные эффекты некоторых природных веществ (сульфатированных полисахаридов и лектинов из морских гидробионтов) по отношению к возбудителям геморрагических лихорадок. Такие соединения могут быть альтернативой синтетическим лекарствам благодаря низкой токсичности, редким побочным эффектам и отсутствию формирования к ним резистентности у вирусов. Кроме сильного противовирусного действия полисахариды и лектины обладают противовоспалительными, иммуномодулирующими, антиоксидантными и антитоксическими свойствами, что является важным для купирования многочисленных нарушений в организме, обусловленных возбудителями вирусных геморрагических лихорадок. В заключительной части обзора рассматриваются перспективы использования этих соединений как основы для создания новых лекарственных препаратов и биологически активных добавок к пище на их основе.

1. Аристова В.А., Колобухина Л.В., Щелканов М.Ю., Львов Д.К. Дифференциация генетических вариантов вирусов Крымской-Конго геморрагической лихорадки. Вопросы вирусологии. 2011; 46 (4): 7–15.

2. Joniec J., Kolodziej M., Bartoszcze M. et al. Res. On prevention and treatment of hemorrhagic fever. Ann Agric Environ Med. 2012; 19 (2): 165–171.

3. Lvov D.K., Shchelkanov M.Yu., Alkhovsky S.V., Deryabin P.G. Zoonotic viruses of Northern Eurasia. Taxonomy and Ecology. Academic Press, 2015; 452.

4. Щелканов М.Ю., Дедков В.Г., Галкина И.В. и др. Районирование африканской природноочаговой провинции в отношении филовирусных лихорадок. Вестник РАМН. 2017; 72 (5): 325–335. doi.org/10.15690/vramn804.

5. Руководство по вирусологии: вирусы и вирусные инфекции человека и животных. Под ред. Д.К.Львова; М.: Медицинское информационное агентство, 2013; 1197. [Rukovodstvo po virusologii: virusy i virusnye infektsii cheloveka i zhivotnykh. Pod red. D.K.L'vova; Moscow: Meditsinskoe Informatsionnoe Agentstvo, 2013; 1197. (in Russian)]

6. Anishchenko M., Щелканов М.Ю., Алексеев В.В. и др. Молекулярные маркеры патогенности вируса Западного Нила. Вопросы вирусологии. 2010; 55 (1): 4–10.

7. Щелканов М.Ю., Магассуба Н., Дедков В.Г. и др. Природный резервуар филовирусов и типы связанных с ними эпидемических вспышек на территории Африки. Вестник РАМН. 2017; 72 (2): 112–119. doi: 10.15690/vramn803.

8. Mariappan V., Pratheesh P., Shanmugam L. et al. Viral hemorrhagic fever: molecular phatogenesisi and current trends of disease management — an update. Current Research in Virological Science. 2021; 2: 100009. doi: 10.1016/j.crivro.2021.100009

9. Lvov D.K., Butenko A.M., Gromashevsky V.L. et al. West Nile and other emerging-reemerging viruses in Russia. NATO Science Series. Series I. Life and Behavior Sciences. Emerging Biological Threat. V. 370. Amsterdam: IOS Press, 2005; 33–42.

10. Онищенко Г.Г., Топорков В.В., Карнаухов И.Г., Удовиченко С.К. Эпидемия лихорадки Эбола в Западной Африке как чрезвычайная ситуация в области биологической безопасности международного значения. Инфекционные болезни. Новости. Мнения. Обучение. 2016; 1: 61–72.

11. Parvez M.K., Parveen S. Evolution and emergence of pathogenic viruses: past, present and future. Intervirology. 2017; 60: 1–7. doi: 10.1159/000478729.

12. Львов Д.Н., Щелканов М.Ю., Джаркенов А.Ф. и др. Популяционные взаимодействия вируса Западного Нила (Flaviviridae, Flavivirus) с членистоногими переносчиками и позвоночными животными в среднем и нижнем поясах дельты Волги (2001–2006 гг.) Вопросы вирусологии. 2009; 2: 36–43.

13. Sikkema R.S., Koopmans M.P.G. Preparing for emerging zoonotic viruses. Encyclopedia of Virology. 2021: 256–266. doi: 10.1016/B978-0-12-814515-9.00150-8.

14. Hassel J.M., Begon M., Ward M.J., Fevre E.M. Urbanization and disease emergence: dynamics at the wildlife-livestock-human interface. Trends Ecol Evol. 2017; 32: 55–67. doi: 10.16/j.tree.2016.09.012

15. Терновой В. А., Щелканов М. Ю., Шестопалов А. М. и др. Выявление вируса Западного Нила в птицах на территории Барабинской и Кулундинской низменностей (Западно-Сибирский пролетный путь) в летне-осенний период 2002 г. Вопросы вирусологии 2004; 49 (3): 52–56.

16. Львов Д. К., Щелканов М. Ю., Колобухина Л. В. и др. Серологический мониторинг арбовирусных инфекций в дельте р. Кубань (данные 2006—2007 гг.) Вопросы вирусологии. 2008; 53 (4): 30–35.

17. Mirsaedi M., Motahari H., Khamesi M.T. et al. Climate change and respiratory infections. Ann Am Thorac Soc. 2016; 13: 1223–1230. doi: 10.1513/Annals ATS.201511-729PS. doi: 10.1513/AnnalsATS.201511-729PS.

18. Щелканов М.Ю., Zoumanigui N., Boiro M.Y., Малеев В.В. Пять мифов о лихорадке Эбола: где кончается вымысел? РМЖ Медицинское обозрение. 2015; 2: 58–66.

19. Rijal P., Elias S.C., Machado S.R. et al. Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell. Reports. 2019; 27(1):172-186.e7. doi: 10.1016/j.celrep.2019.03.020.

20. Щелканов М.Ю., Magassouba N.F., Boiro M.Y., Малеев В.В. Причины развития эпидемии лихорадки Эбола в Западной Африке. Lvrach. 2014; (11): 30–36. http://www.lvrach.ru/2014/11/15436092/

21. Liu J., Pei T., Mu J. et al. Systems pharmacology uncovers the multiple mechanisms of Xijiao Dihuang Decoction for the treatment of viral hemorrhagic fever. Res. Article. 2016; 2016: 9025036. doi: 10/1155/2016/ 9025036.

22. Reis J.G., Cadamuro R.D., Cabral A.C. et al. Broad spectrum algae compounds against viruses. Front Microbiol. 2022; 12: 809296. doi: 10.3389/fmicb.2021.809296.

23. Alam M. A., Parra-Saldivar R., Bilal M. et al. Algae-derived bioactive molecules for the potential treatment of SARS-CoV-2. Molecules. 2021; 26: 2134. doi: 10.3390/molecules26082134.

24. Reinolds D., Huesemann M., Edmundson S. et al. Viral inhibitors derived from macroalgae, microalgae and cyanobacteria: a reviw of antiviral throughout pathogenesis. Algal Res. 2021; 57: 102331. doi: 10.1016/j.algal.2021.102331.

25. Hammed I., Ozogul F., Ozogul Y., Regenstein J.M. Marine bioactive compounds and their health benefits: a review. Compr Rev Food Sci. 2015; 14: 446–465. doi: 10.1111/1541-4337.12136.

26. Zhong H., Gao X., Cheng C. et al. The structural characteristics of seaweed polysaccharides and their application in gel drug delivery systems. Mar Drugs. 2020; 18: 658. doi: 10.3390/md18120658.

27. Valcarcel J., Novoa-Carballal R., Perez-Martin R.I. et al. Glycosaminoglycans from marine sources as therapeutic agents. Biotechnology Advances. 2017; 35 (1): 711–725. doi: 10.1016/j.biotechadv.2017.07.008.

28. Arima K., Fujita H., Toita R. et al. Amounts and compositional analysis of glycosaminoglycans in the tissue of fish. Carbohydrate Res. 2013; 336:25–32. doi: 10.1016/j.carres.2012.11.010.

29. Zahra Z., Choo D.H., Lee H., Parveen A. Cyanobacteria: review of current potentials and applications. Environments. 2020; 7 (2): 13. doi:10.3390/environments7020013

30. Nandagopal P., Steven A.N., Chan L-W. et al. Bioactive metabolites produced by cyanobacteria for growth adaptation and their pharmacological properties. Biology. 2021; 10 (10): 1061. doi: 10.3390/biology10101061.

31. Wang W., Wang S-X., Guan H.-S. The antiviral activities and mechanisms of marine polysaccharides: an overview. Mar Drugs. 2012; 10 (12): 2795–2816. doi: 10.3390/md10122795.

32. Alvarez-Vinas M., Souto S., Florez-Fernandez N. et al. Antiviral activity of carrageenans and processing implications. Mar Drugs. 2021; 19: 437. doi: 10.3390/md19080437.

33. Asker M.S., Kady E.M., Mahmoud M.G. New trends of the polysaccharides as a drug. World J Agr Soil Sci. 2019; 3 (5): 000572. doi: 10.33552/WJASS.2019.

34. Shi D., Sheng A., Chi L. Glycosaminoglycan-protein interactions and their roles in human disease. Front Mol Biosci. 2021 Mar 9; 8: 639666. doi: 10.3389/fmolb.2021]

35. Hans N., Malik A., Naik S. Antiviral activity of sulfated polysaccharides from marine algae and its application in combating combating COVID-19: mini review. Bioresour. Technol Rep. 2021; 13: 100623. doi:10.1016/j.biteb.2020.100623.

36. Claus-Desbonnet H., Nikly E., Nalbantova V. et al. Polysaccharides and their derivates as potential antiviral molecules. Viruses. 2022; 14: 426. doi: 10.3390/v14020426.

37. Allen M.M.F., Schols D. Dengue virus entry as target for antiviral therapy. J Trop Med. 2012; 628475. doi: 10.1155/2012/628475.

38. Rodrigues J.A.G., Eloy Y.R.G., Oliveira E. de Sousa et al. An anti-dengue and antiherpetic polysulfated fraction isolated from the green seaweed Caulerpa cupressoides inhibits thrombin generation in vitro. Acta Scientiarum. Biological Sciences. 2017; 3 (2): 149–159. doi: 10.4025actascibiolsci.v3912.28081.

39. Kim S.Y., Li B., Linhardt R.J. Pathogenesis and inhibition of flaviviruses from a carbohydrate perspective. Pharmaceuticals. 2017; 10 (2): 44. doi: 10.3390/ph10020044.

40. Fernandez-Romero J.A., Paglini M.G., Priano C. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687. doi: 10.3390/md19120687.

41. Huskens D., Schols D. Algal lectins as potential HIV microbicide candidates. Mar. Drugs. 2012; 10: 1476–1497. doi: 10.3390/md10071476.

42. Singh R.S., Walia A.K. Lectins from red algae and their biomedical potential. J Appl Phycol. 2018; 30: 1833–1858. doi: 10.1007/s10811-017-1338-5.

43. Abel J., Romero J.A.F., Pagglini M.Q. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687. doi:10.3390/md19120687.

44. Mitchell C.A., Ramessar K., O’Keefe B.R. Antiviral lectins: selective inhibitors of viral entry. Antiviral Res. 2017; 142: 37–54. doi:10.1016/j.antiviral.2017.03.007.

45. Barre A., Simplicien M., Benoist H. et al. Mannose-specific lectins from marine algae: diverse structural scaffolds associated to common virucidal and anti-cancer properties. Mar Drugs. 2019; 17 (8): 440. doi: 10.3390/md17080440.

46. Romero F.J.A., Paglini M.G., Priano C. et al. Algal and сyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19: 687; doi:10.3390/md19120687.

47. Barton C., Kouocam J.C., Lasnik A.B. et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffitsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014; 58 (1): 120–127. doi: 10.1128/AAC.01407-13.

48. Lusvarghi S., Bewley C. Griffitsin: an antiviral lectin with outstanding therapeutic potential. Viruses. 2016; 8 (10): 296. doi: 10.3390/v8100296.

49. Lee C. Griffitsin, a highly potent broad-spectrum antiviral lectin from red algae: from discovery to clinical application. Mar Drugs. 2019; 17 (10): 567. doi: 10.3390/md17100567.

50. Singh R.S., Thakur S.R., Bansal P. Algal lectins as promising biomolecules for biomedical research. Crit Rev Microbiol. 2013; 1–12. Early online4.

51. Ryu W-S. Molecular virology of human. Pathogenic Viruses. 2017; 31–45. doi: 10.1016/B978-0-12-800838-6.00003-5.

52. Bianculli R.H., Mase J.D., Schulz M.D. Antiviral polymers: past approaches and future possibilities. Macromolecules. 2020; 53: 9158–9186. doi:10.1021/acs.macromol.0c01273.

53. Bi X., Yi S., Zhang A. et al. Epidemiology of hemorrhagic fever with renal syndrome in Taian area. Sci Rep. 2021; 11 (1): 11596. doi: 10.1038/s41598-021-91029-1.

54. Noack D., Goeijenbier M., Reusken C.B.E.M. et al. Orthohantavirus pathogenesis and cell tropism. Front Cell Infect Microbiol. 2020; 10: 399. doi:10.3389/fcimb.2020.00399.

55. Lupusoru G., Lupusoru M., Ailincai I. et al. Hemorrhagic fever with renal syndrome: a pathology in whose diagnosis kidney biopsy plays a major role. Exp Ther Med. 2021; 22 (3): 984. doi.org/10.3892/etm.2021.10416.

56. Mir S. Hantavirus induced kidney diseases. Front Med (Lausanne). 2022; 8: 795340. doi: 10.3389/fmed.2021.795340.

57. Liang W., Gu X., Li X. et al. Mapping the epidemic changes and risks of hemorrhagic fever with renal syndrome in Shaanxi Province, China, 2005–2016. Sci Rep. 2018; 8: 749. doi: 10.1038/s41598-017-18819-4.

58. Yashina L.N., Smetannikova N.A., Kushnareva T.V. et al. Hemorrhagic fever with renal syndrome in Vladivostok city, Russia. Front. Publ Health. 2021; 9: 620279. doi: 10.3389/fpubh.2021.620279.

59. Иванова А.В., Попов Н.В., Карнаухов И.Г., Чумачкова Е.А. Хантавирусные болезни: обзор эпидемиологической ситуации и эпидемиологических рисков в регионах мира. Проблемы особоопасных инфекций. 2021; 1: 23–31. doi: 10.21055/0370-1069-2021-1-23-31.

60. Mayor J., Engler O., Rothenberger S. Antiviral efficacy of ribavirin and favipiravir against hantaan virus. Microorganisms. 2021; 9 (6): 1306. doi: 10.3390/microorganisms9061306.

61. Макаренкова И.Д. Молекулярно-клеточные механизмы активации врожденного иммунитета сульфатированными полисахаридами бурых водорослей. Дисс. … докт. мед. наук. М. 2013; 231.

62. Сifuentes-Munoz N., Salazar-Quiroz N., Tishler N.D. Hantavirus Gn and Gc envelope glycoproteins: key structural units for virus cell entry and virus assembly. Viruses. 2014; 6 (4): 1801–1822. doi: 10.3390/v6041801.

63. Mittler E., Dieterle M.E., Kleinfelter L.M. et al. Hantavirus entry:perspectives and recent advances. Adv Virus Res. 2019; 104: 185–224. doi:10.1016/bs.aivir.2019.07.002.

64. Dietele M.E., Sola-Riera C., Ye C. et al. Genetic depletion studies inform receptor usage by virulent hantaviruses in human endothelial cells. eLife. 2021; 10: e69708. doi: 10.7554/eLife.69708.

65. Krylova N.V., Silchenco A., Pott A.B. et al. In vitro anti-orthohantavirus activity of the high- and low-molecular-weight fractions of fucoidan from the brown alga Fucus evanescens. Mar Drugs. 2021; 19 (10): 577. doi: 10.3390/md19100577.

66. Shrivastava-Ranjan P., Lo M.K., Chatterjee P. et al. Hantavirus infection is inhibited by griffitsin in cell culture. Front Cell Infect Microbiol. 2020; 10: 561502. doi: 10.3389/fcimb.2020.561502.

67. Lo Y-L., Liou G-G., Lyu J-H. et al. Dengue virus infection is through a cooperative interaction between a mannose receptor and CLEC5A on macrophage as a multivalent hetero-complex. PLoS ONE. 2016; 11 (11): e0166474. doi: 10.1371/journal.pone.0166474.

68. Gomaa H., Elshoubaky G.A. Antiviral activity of sulfated polysaccharides carrageenan from some marine seaweeds. Int J Curr Pharm Rev Res. 2015; 7 (1): 34–42.

69. Hasan M.J., Tabassum T., Sharif M. et al. Comparison of clinical manifestation of dengue fever in Bangladesh: an observation over a decade. BMC Infect Dis. 2021, 21 (1): 1113. doi: 10.1186/s12879-021-06788-z.

70. Soneja S., Tsarouchi G., Lumbroso D. et al. A review of dengue’s historical and future health risk from a changing climate. Curr Envir Health Rpt. 2021; 8: 245–265. doi: 10.1007/s40572-021-00322-8.

71. Murugesan A., Manoharan M. Emerging and reemerging viral pathogens. Chapter 16 — Denge virus. 2020; 281–359. doi: 10.1016/B978-0-12-819400-3.00016-8.

72. Cagno V., Tseligka E.D., Jones S.T., Tapparel C. Heparan sulfate proteoglycans and viral attachment:true receptors or adaptation Bias?. Viruses. 2019; 11 (7): 596. doi: 10.3390/v11070596.

73. Liu P., Ridilla M., Patel P. et al. Beyond attachment:roles of DC-SIGN in dengue virus infection. Traffic. 2017; 18 (4): 218–231. doi: 10.1111/tra.12469.

74. Sung P-S., Chang W.C., Hsieh S-L. CLEC5A: a promiscuous pattern recognition receptor to microbes and beyond. Lectin in Host Defense against Microbial Infections. 2020; 1204: 5773. doi: 10.1007/978-981-15-1580-4_3.

75. Songprakhon P., Limjindaporn T., Perng G.C. et al. Human glucose-regulated protein 78 modulates intracellular production and secretion of nonstructural protein 1 of dengue virus. J Gen Virol. 2018; 99 (10): 1391–1406. doi: 10.1099/jgv.0.001134.

76. Aguilar-Briseno J.A., Upasani V., Bram M. et al. TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis. Nat Commun. 2020; 11: 3177. doi: 10.1038/s41467-020-16849-7.

77. Zaitseva E., Yang S.T., Melikov K. et al. Virus ensures its fusion in late endosomes using compartment-specific lipids. PLoS Pathog. 2010; 6 (10):e1001131. doi: 10.1371/journal.ppat.1001131.

78. Screaton G., Mongkolsapaya J., Yacoub S., Roberts C. New insight into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015; 15 (12): 745–759. doi: 10.1038/nri3916.

79. Acosta E.G., Bartenschlager R., Baumert T., Schuster C. The quest for host targets to combat dengue virus infections. Curr Opin Virol. 2016; 20:47–54. doi: 10.1016/j.coviro.2016.09.003.

80. Balsitis S.J., Coloma J., Castro G. et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg. 2009; 80 (3): 416–424.

81. Begum F., Das S., Mukherju D. et al. Insight into the tropism of dengue virus in humans. Viruses. 2019; 11 (2): 1136. doi: 10.3390/v11121136.

82. Roy S.K., Bhattacharjee S. Dengue virus: epidemiology, biology and disease aetiology. Can J Microbiol. 2021; 67 (10): 687–702. doi: 10.1139/cjm-2020-0572.

83. Nedjadi T., El-Kafrawy S., Sohrab S.S. et al. Tackling dengue fever: current status and challenges. Virol J. 2015; 12: 212. doi: 10.1186/s12985-015-0444-8.

84. Lopes J.L., Quinteiro V.S.T., Wouk J. et al. Sulfonated and carboxymethylated β-glucan derivatives with inhibitory activity against Herpes and Dengue viruses. Int J Mol Sci. 2021; 22 (20): 11013. doi: 10.3390/ijms222011013.

85. Koishi A.C., Zanello P.R., Bianco E.M. et al. Screening of Dengue virus antiviral activity of marine seaweeds by an in situ enzyme-linked immunosorbent assay. PLoS ONE. 2012; 7 (12): e51089. doi: 10.1371/journal.pone.0051089

86. Trost B., Smit J.M. Recent advances in antiviral drug development towards dengue virus. Curr Opin Virol. 2020; 43: 9–21. doi: 10.1016/j.coviro.2020.07.009.

87. Talarico L.B., Pujol C.A., Zibetti R.G.M. et al. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res. 2005; 66 (2–3): 103–110. doi: 10.1016/j.antiviral.2005.02.001.

88. Talarico L.B., Damonte E.B. Interference in dengue virus adsorbtion and uncoating by carrageenans. Virology. 2007; 363 (2): 473–485. doi: 10.1016/j.virol.2007.01.043.

89. Talarico L.B., Noseda M.D., Ducatti D.R.B. et al. Differential inhibition of dengue virus infection in mammalian and mosquito cells by iota-carrageenan. J Gen Virol. 2011; 92: 1332–1342. doi: 10.1099/vir.0028522-0.

90. Wikan N., Kuadkitkan A., Smith D.R. The Aedes aegypti cell line CCL125 is dengue virus permissive. J Virol Methods. 2009; 157 (2): 227–230. doi:10.1016/j.jviromet.2008.12.019. Epub 2009 Jan 19.

91. Pujol C.A., Estevez J.M., Carlucci M.J. et al. Novel DL-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus. Antivir Chem Chemother. 2002; 13: 83–89. doi: 10.1177/095632020201300202.

92. Pujol C.A., Ray S., Ray B., Damonte E. Antiviral activity against dengue virus of diverse classes of algal sulfated polysaccharides. Int J Biol Macromol. 2012; 51 (4): 412–416. doi: 10.1016/j.ijbiomac.2012.05.028.

93. Piccini L.E., Carro A.C., Quintana V.M., Damonte E.B. Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan. Virus Res. 2020; 290: 198150. doi: 10.1016/j.virusres.2020.198150.

94. Hidari K.I.P.J., Takahashi N., Arihara M. et al. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochem Biophys Res Commun. 2008; 376 (1): 91–95. doi: 10.1016/j.bbrc.2008.08.100

95. Hidari K.I.P., Abe T., Suzuki T. Carbohydrate-related inhibitors of dengue virus entry. Viruses. 2013; 5 (2): 605–618. doi: 10.1177/095632020201300202

96. Fuentes P.E.P., Benito J.S.S., Ruiz C.H.M. et al. Actividad anti-dengue in vitro del alga marina Hypnea cervicornis. Rev Mex Cienc Farm. 2017; 48 (1).

97. Ding L., Ma Y., Huang B., Chen S. Effects of seawater salinity and pigment contents in Hypnea cervicornis. J. Agardh (Gigartinales, Rhodophyta). Biomed Res Int. 2013; 594308. doi:10.1155/2013/594308.

98. Alexandre K.B., Gray E.S., Mufandu H. et al. The lectins griffitsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells. Virology. 2012; 423 (2): 175–186. doi:10.1016/j.virol.2011.12.001.

99. Garrison A.R., Giomarelli B.G., Lear-Rooney C.M. et al. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antivir Res. 2014; 0: 1–7. doi: 10.1016/j.antiviral.2014.09.0123.

100. Mazalowska M., Kouokam J.C. Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections. Review article. Open Access. Hindawi BioMed Res Int. 2018; 2018: 3750646. doi: 10.1155/2018/3750646.

101. Kouokam J.C., Lasnik A.B., Palmer K.E. Studies in a murine model confirm the safety of griffitsin and advocate its further development as a microbicide targeting HIV-1 and other enveloped viruses. Viruses. 2016; 8:311. doi: 10.3390/v8110311.

102. De Clercq E. Ebola virus(EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015; 93 (1): 1–10. doi: 10.1016/j.bcp.2014.11.008.

103. Singh R.S.; Walia A.K. Lectins from red algae and their biomedical potential. J Appl Phycol. 2018, 30: 1833–1858. doi: 10.1007/s10811-017-1338-5.

104. Barrientos L.G., O’Keefe B.R., Bray M., Sanchez A., Gronenborn A.M., Boyd M.R. Cyanovirin-N binds to the viral surface glycoprotein GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003; 58: 47–56. doi: 10.1016/s0166-3542(02)00183-3.

105. El-Shafei R., Hegazy H., Acharya B. A review of antiviral and antioxidant activity of bioactive metabolite of macroalgae within an optimized extraction method. Energies. 2021; 14: 3092. doi: 10.3390/en14113092.

106. Barrientos L.G., Lasala F., Otero J.R. et al. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with Filovirus envelope glycoproteins. J Infect Dis. 2004; 189 (8): 1440–1443. doi: 10.1086/382658.

107. Liu J., Obaidi I., Nagar S et al. The antiviral potential of algal-derived macromolecules. Curr Res Biotechnol. 2021; 3: 120–134. doi:10.1016/j.crbiot.2021.04.003.

108. Walia S., Singh M. Tracing plants potential effective against dengue virus: a review. Int J Innovat Res Multidisciplinar Field. 2021; 7 (5): available online on-www.IJIRMF.COM.

109. Ray B., Ali I., Jana S. et al. Antiviral strategies using natural source-derived sulfated polysaccharides in the light of the COVID-19 pandemic and major human pathogenic viruses. Viruses 2021; 14 (1): 35. doi:10.3390/v14010035.

110. Pavliga S.N., Kompanets G., Tsygankov V.Y. The experimental research (in vitro) of carrageenans and fucoidans to decrease activity of Hantavirus.Food Environl Virol. 2016; 8: 120–124. doi: 10.1007/s12560-016-9233-9.

111. Salvador B., Sexton N.R., Carrion R. et al. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol. 2013; 87 (6):3295–3304. doi: 10.1128/JVI.01621-12